All News
Risks associated with mortality in VEXAS
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition.
Read Article
Increased age at PSO diagnosis was significantly associated with shorter transition time between PSO and PsA diagnoses. No other variables, including BSA, were associated with time to transition @RheumNow #ACR21 Abst#1798 https://t.co/fLPBHKAMAc
Dr. Antoni Chan synovialjoints ( View Tweet)
Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/TxyE4Uqttq https://t.co/Eykxwmcc44
Dr. Rachel Tate uptoTate ( View Tweet)
Secukinumab in GCA, phase 2 (TitAIN):
I can't deny this is promising, but phase 2 needs to be
interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def)
@drpnash: "Bring on the phase 3 trials"
(recruitment started👀)
#ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ
David Liew drdavidliew ( View Tweet)
#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA
⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful
⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC
⭐️Ok to continue IL1i
▶️13/14 pts remission
▶️ SAEs: 1 CMV reactivation
https://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC
Links:
Eric Dein ericdeinmd ( View Tweet)
I am still obsessed with the name MAGIC syndrome -mouth and genital ulcers with inflamed cartilage!!
14% of patients with relapsing polychondritis have this! They also have features of aortitis, Raynaud's phenomenon and anticollagen II antibodies @rheumnow #ACR21 abt#1876 https://t.co/UlQUZlBPfx
Bella Mehta bella_mehta ( View Tweet)
Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062
Bella Mehta bella_mehta ( View Tweet)
#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What if a celebrity had #Scleroderma? Would that ⬆️attention & funding for this rare disease? See what Big Bird says @RheumNow #ACR21 ?affected #PetsofACR @RheumNow @scleroderma @SclerodermaCAN audio-13.m4a
Janet Pope Janetbirdope ( View Tweet)
#ACR21 L21. REOVAS: RTX for EGPA
⭐️CYC traditionally preferred for 5-factor score>0
▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction
▶️No diff in ANCA+/-, naive v relapse, FFS
https://t.co/cuM9LcEr4u @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
#Rituximab NOT different from conventional Rx in #eGPA #churgstrauss abst#L21 v small study, 60% ANCA neg #ACR21 @RheumNow https://t.co/tO1vAF18y9
Janet Pope Janetbirdope ( View Tweet)
Miss anything from Day 1? We are sharing the best #ACR21 abstracts from Day 1.
https://t.co/YZ3jwW0Abu https://t.co/gvWCrIbWuG
Links:
Dr. John Cush RheumNow ( View Tweet)
Emapalumab (IFNg inhibitor) Effective in severe MAS (Ferritin 25K, failed anakinra, GC)- 14 pts (2-25 yrs; 4/14 sJIA)-13/14 remission, w rapid drops in CXCL9, Ferritin, ALT, DDimers & GC dose #ACR21 ABst LB20 https://t.co/05oW5C8Waf https://t.co/ecEkt3MY83
Links:
Dr. John Cush RheumNow ( View Tweet)
Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting.
https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn
Links:
Dr. John Cush RheumNow ( View Tweet)
Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additional biologic trial. Former smoker &PsA duration correlated w/ discontinuation. most commonly reason for d/c TNFi was secondary failure (33%). infliximab had lower d/c rate https://t.co/BXd2ALX2qo
Olga Petryna DrPetryna ( View Tweet)
#ACR21 L17: Heterologous vs Homologous Booster vax
▶️RTX non-responders to mRNA: Randomized to mRNA 3rd dose vs AZ vax
⭐️Majority of pts develop immune response (humoral and/or cellular) after 3rd dose, no statistical diff b/w groups
@Rheumnow https://t.co/cuM9LcEr4u https://t.co/cmNBNSIoOl
Links:
Eric Dein ericdeinmd ( View Tweet)
What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion 30% with 2 #COVIDVaccination. With 3rd vaccine dose up to 94% can have immune response! Pts need their 3rd vaccination @RheumNow #ACR21 #ACRBest abstL17 https://t.co/0GHOuoqPKQ
Janet Pope Janetbirdope ( View Tweet)
Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific inflammatory pathways (IL-23, IL-12, Type I IFN). Listen to my interview with Prof. Oliver Fitzgerald on this and his highlights https://t.co/3UJCwbHsLC
@RheumNow #ACR21 Abst#490 https://t.co/OWZDHhcQ9q
Dr. Antoni Chan synovialjoints ( View Tweet)
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
Dr. Rachel Tate uptoTate ( View Tweet)
👉29% of pts on RTX fail to mount a humoral OR cellular response to #COVIDvaccine & have⬆️hosp,⬆️hosp stay,⬆️severity, persistent viremia,⬆️deaths)
👉study adding booster (AZ or mRNA) overcomes this, enhancing humoral and cellular response
#ACR21 @rheumnow Abst#L17 https://t.co/yuX1TT6ZBF
TheDaoIndex KDAO2011 ( View Tweet)